Document is current
Any future updates will be listed below
-
Authors
Vandervelden, Stefanie
Cortens, Bente
Fieuws, Steffen
Eegdeman, Wilma
Malinverni, Stefano
Vanhove, Philippe
Monsieurs, Koen
Breuls, Jan
Hubloue, Ives
Stifkens, François
Creteur, Jacques
Wauters, Lina
Desruelles, Didier
,
-
Funding
Funding for this research was provided by:
Belgian Health Care Knowledge Centre (KCE19-1237)
- License Information
-
More Information
Article History
Received: 9 December 2024
Accepted: 23 March 2025
First Online: 23 April 2025
Declarations
:
: The trial protocol was approved by a central ethics committee and the Belgian Federal Agency for Medicines and Health Products through the Clinical Trial Regulation (CTR) pilot procedure. CTR Pilot Number: 389. All patients or their legally acceptable representative (LAR) provided written informed consent. To ensure timely initiation of medication administration (within 6 h), a process of delayed consent was employed, enrolling patients in the clinical trial and obtaining consent as soon as practical from the patient or their LAR.
: Not Applicable.
: The authors declare no competing interests.
